Recent trends in 3D bioprinting technology for skeletal muscle regeneration. 2024

Shabnam Sabetkish, and Peter Currie, and Laurence Meagher
Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia; ARC Training Centre for Cell and Tissue Engineering Technologies, Monash University, Clayton, VIC 3800, Australia.

Skeletal muscle is a pro-regenerative tissue, that utilizes a tissue-resident stem cell system to effect repair upon injury. Despite the demonstrated efficiency of this system in restoring muscle mass after many acute injuries, in conditions of severe trauma such as those evident in volumetric muscle loss (VML) (>20 % by mass), this self-repair capability is unable to restore tissue architecture, requiring interventions which currently are largely surgical. As a possible alternative, the generation of artificial muscle using tissue engineering approaches may also be of importance in the treatment of VML and muscle diseases such as dystrophies. Three-dimensional (3D) bioprinting has been identified as a promising technique for regeneration of the complex architecture of skeletal muscle. This review discusses existing treatment strategies following muscle damage, recent progress in bioprinting techniques, the bioinks used for muscle regeneration, the immunogenicity of scaffold materials, and in vitro and in vivo maturation techniques for 3D bio-printed muscle constructs. The pros and cons of these bioink formulations are also highlighted. Finally, we present the current limitations and challenges in the field and critical factors to consider for bioprinting approaches to become more translationa and to produce clinically relevant engineered muscle. STATEMENT OF SIGNIFICANCE: This review discusses the physiopathology of muscle injuries and existing clinical treatment strategies for muscle damage, the types of bioprinting techniques that have been applied to bioprinting of muscle, and the bioinks commonly used for muscle regeneration. The pros and cons of these bioinks are highlighted. We present a discussion of existing gaps in the literature and critical factors to consider for the translation of bioprinting approaches and to produce clinically relevant engineered muscle. Finally, we provide insights into what we believe will be the next steps required before the realization of the application of tissue-engineered muscle in humans. We believe this manuscript is an insightful, timely, and instructive review that will guide future muscle bioprinting research from a fundamental construct creation approach, down a translational pathway to achieve the desired impact in the clinic.

UI MeSH Term Description Entries

Related Publications

Shabnam Sabetkish, and Peter Currie, and Laurence Meagher
July 2022, Pharmaceutics,
Shabnam Sabetkish, and Peter Currie, and Laurence Meagher
December 2022, Hepatobiliary surgery and nutrition,
Shabnam Sabetkish, and Peter Currie, and Laurence Meagher
June 2019, Small (Weinheim an der Bergstrasse, Germany),
Shabnam Sabetkish, and Peter Currie, and Laurence Meagher
May 2021, Bioactive materials,
Shabnam Sabetkish, and Peter Currie, and Laurence Meagher
January 2022, Frontiers in bioengineering and biotechnology,
Shabnam Sabetkish, and Peter Currie, and Laurence Meagher
March 2023, Advanced healthcare materials,
Shabnam Sabetkish, and Peter Currie, and Laurence Meagher
January 2018, Regenerative medicine,
Shabnam Sabetkish, and Peter Currie, and Laurence Meagher
January 2017, Advanced healthcare materials,
Shabnam Sabetkish, and Peter Currie, and Laurence Meagher
November 2022, Biomaterials advances,
Shabnam Sabetkish, and Peter Currie, and Laurence Meagher
February 2022, Micromachines,
Copied contents to your clipboard!